C. Spehr

Prevalence and risk factors of actinic keratoses in Germany--analysis of multisource data.

In Europe, only few and inconsistent data on the prevalence and treatment of actinic keratoses (AK) are available.

German psoriasis registry PsoBest: objectives, methodology and baseline data.

The German psoriasis registry PsoBest records the long‐term efficacy, safety, patient benefit and treatment regimens of psoriasis.

Psoriasis registries worldwide: systematic overview on registry publications

Safety and efficacy of new treatments are analyzed in clinical trials but their capacity to show potential effects of long‐term treatment and more than short latency of onset is limited. To meet this challenge, patient registries (of treatments or diseases) collect prospective data of real‐world patients in daily practice without tight selection of patients.

Health care characteristics of basal cell carcinoma in Germany: the role of insurance status and socio-demographic factors

In Germany population‐based data on health care of basal cell carcinoma (BCC) are rare.

Efficacy and Survival of Systemic Psoriasis Treatments: An Analysis of the Swiss Registry SDNTT.

Background: The Swiss psoriasis registry SDNTT (Swiss Dermatology Network for Targeted Therapies) records the long-term safety and effectiveness of systemic treatment regimens for psoriasis. Patients and Methods: Patients with moderate to severe psoriasis are included in the SDNTT when treatment with a conventional systemic agent or biologic is initiated that was not previously used by the respective patient. Patients are followed over a 5-year period. Clinical data are obtained every 3-6 months using standardized case report forms. Here, baseline data and follow-up data for 1 year of patients included from October 2011 until December 2014 were analyzed. Results: Within 39 months, 323 patients from 7 tertiary dermatology centers in Switzerland were recruited in the SDNTT; 165 patients received biologics and 158 conventional systemic therapies. Patients treated with biologics had a significantly higher severity (PASI 11.3 vs. 9.2, BSA 15.6 vs.11.9, psoriatic arthritis 36.4 vs. 10.8%; p ≤ 0.005, p ≤ 0.013, p ≤ 0.001) and a longer duration of illness (19.2 vs. 14.4 years, p ≤ 0.003) compared to patients starting a conventional systemic treatment. PASI reduction was satisfying in both treatment groups, with 60.6% of patients treated with biologics achieving PASI75 after 1 year compared to 54.2% of patients receiving conventional systemic drugs (nonsignificant). On average, the drug survival in patients receiving a biologic therapy was significantly longer than those receiving conventional systemic treatments (30.5 vs. 19.2 months, p ≤ 0.001). Conclusions: In the real-world setting of a prospective national therapy registry, the application of current therapeutic guidelines for patients with moderate to severe psoriasis resulted in a PASI reduction of approximately 70% within the first year of treatment, but current therapeutic targets of PASI75 and PASI90 were reached in only 58 and 36% of patients, respectively, at 1 year, highlighting a gap in efficacy between selective clinical trials and the real-world setting.

The Impact of Age on Psoriasis Health Care in Germany.

Inequality between age groups has been demonstrated in the prescription of biologics, yet systematic real‐world data about age‐related differences in psoriasis care are missing.

Treatment Satisfaction in Psoriasis: Development and Use of the PsoSat Patient Questionnaire in a Cross-Sectional Study

Introduction: Evidence supports the potential value of matching patient preferences to treatment recommendations. The aim of the study was to design and validate a questionnaire on treatment satisfaction for clinical decision-making. Methods: We performed a comprehensive literature search identifying measurable indicators. The complete item pool was condensed to a core set by a multidisciplinary expert panel and tested in a multicentre, observational, cross-sectional study. Results: The questionnaire consisted of 8 questions, rated on a 5-point Likert scale. In total, 213 dermatology centres included 2,084 patients. The mean disease duration was 19 years. A majority of patients (82.8%) was moderately to very satisfied. 108 patients (5.8%) felt to be bothered by side effects, and 32.1% ascertained that the current therapy had been conducted for too long without success. Discussion: The PsoSat Questionnaire was shown to be a reliable and valid instrument for measuring therapy-related satisfaction. Further research on its implementation in clinical decision-making is necessary to finally evaluate the benefit of this tool.

Deutsches Psoriasis-Register PsoBest: Zielsetzung, Methodik und Basisdaten

Zusammenfassung Hintergrund: Das Deutsche Psoriasis-Register PsoBest erfasst die Wirksamkeit, Sicherheit, Patientennutzen und Modalitäten der Psoriasistherapie im Langzeitverlauf. Patienten und Methodik: In PsoBest werden Patienten mit mittelschwerer und schwerer Psoriasis bei Ersteinstellung auf ein konventionelles Systemtherapeutikum oder Biologikum eingeschlossen und über fünf Jahre beobachtet. Die Basisdaten der bis zum 31.12.2012 eingeschlossenen Patienten werden präsentiert und mit denen der bundesweiten Versorgungsstudie PsoHealth 2007 (n = 2 009) verglichen. Ergebnisse: In PsoBest sind 602 dermatologische Praxen und Kliniken gemeldet, von denen 199 bis zum 31.12.2012 n = 2 556 Patienten einschlossen (63 % Praxen, 37 % Kliniken). Initial Biologika erhielten n = 808 (316 Adalimumab, 34 Efalizumab, 209 Etanercept, 75 Infliximab, 22 Golimumab, 152 Ustekinumab) und konventionelle Systemtherapeutika n = 1 651 (928 Fumarsäureester, 518 Methotrexat, 161 Ciclosporin A, 191 andere Präparate oder PUVA-Therapie). Die Patienten in PsoBest hatten im Vergleich zu PsoHealth einen höheren mittleren Schweregrad (PASI 14,7 vs. 10,1; DLQI 11,0 vs. 7,5; EQ-5D VAS 54,0 vs. 64,5), kürzere Erkrankungsdauer (18,2 vs. 21,3 J.), niedrigeres Alter (47,3 vs. 51,5), sowie häufiger Anteile an Psoriasis-Arthritis (20,5 vs. 19,1 %) und Nagelpsoriasis (55,0 vs. 35,6 %). Patienten unter Biologika-Therapie waren im Durchschnitt jünger, häufiger männlich, schwerer erkrankt und wiesen eine höhere Komorbidität auf. Schlussfolgerungen: Die Patienten in PsoBest repräsentieren Psoriasispatienten mit hohem Schweregrad und starkem Leidensdruck.

Versorgungsmerkmale des Basalzellkarzinoms in Deutschland: Die Rolle von Versichertenstatus und soziodemographischen Faktoren

Zur Versorgung des Basalzellkarzinoms (BCC) liegen in Deutschland nur wenige bevölkerungsbezogene Daten vor.